SCHEMBL3680834

SCHEMBL3680834

CCCCNC[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)CO

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.52
LMNA P02545 3/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
TDP1 Q9NUW8 1/20 0.42
TSHR P16473 2/20 0.39
PKM P14618 1/20 0.36
ANPEP P15144 1/20 0.36
ERAP2 Q6P179 1/20 0.36
ALDH1A1 P00352 1/20 0.36
CYP2D6 P10635 2/20 0.33
SPHK1 Q9NYA1 1/20 0.33
GMNN O75496 1/20 0.33
POLB P06746 1/20 0.33
THPO P40225 1/20 0.33
MTOR P42345 1/20 0.33
BLM P54132 1/20 0.33
TP53 P04637 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3373994 1.00 KDM4E (0.52) KDM4ELMNAL3MBTL1TDP1TSHR
SCHEMBL22321686 1.00 KDM4E (0.52) KDM4ELMNAL3MBTL1TDP1TSHR
Hydrochloric Acid SCHEMBL7165571 0.98 KDM4E (0.50) KDM4ELMNAL3MBTL1TDP1TSHR
SCHEMBL4128441 0.94 KDM4E (0.50) KDM4ELMNAL3MBTL1TDP1TSHR
SCHEMBL3801934 0.92 KDM4E (0.48) KDM4ELMNAL3MBTL1TDP1TSHR
SCHEMBL8433089 0.92 KDM4E (0.48) KDM4ELMNAL3MBTL1TDP1TSHR
SCHEMBL14118625 0.92 KDM4E (0.48) KDM4ELMNAL3MBTL1TDP1TSHR
SCHEMBL12510924 0.92 KDM4E (0.48) KDM4ELMNAL3MBTL1TDP1TSHR
SCHEMBL17678369 0.92 KDM4E (0.48) KDM4ELMNAL3MBTL1TDP1TSHR
SCHEMBL617140 0.92 KDM4E (0.48) KDM4ELMNAL3MBTL1TDP1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100087399-A1 USE OF 9-OXOACRIDINE-10-ACETIC ACID, SALTS AND ESTERS THEREOF IN COMBINATION THERAPY OF OVARIAN CANCER SURKOV KIRILL GENNADIEVICH 2010-04-08 US disclosed
WO-2008121028-A2 USE OF 9-OXOACRIDINE-10-ACETIC ACID, SALTS AND ESTERS THEREOF IN COMBINATION THERAPY OF OVARIAN CANCER SURKOV KIRILL GENNEDIEVICH (RU) 2008-10-09 WO disclosed
WO-2008024026-A2 USE OF 9-OXOACRIDINE-10-ACETIC ACID, ITS SALTS AND ESTERS FOR THE TREATMENT, PROPHYLAXIS OR RELAPSE PREVENTION OF PROSTATE CANCER SURKOV KIRILL GENNADIEVICH (RU) 2008-02-28 WO disclosed
WO-2008024027-A2 USE OF 9-OXOACRIDINE-10-ACETIC ACID, ITS SALTS AND ESTERS FOR ENHANCING THE EFFICACY OF ANTIANDROGENIC TREATMENT SURKOV KIRILL GENNADIEVICH (RU) 2008-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087399-A1 USE OF 9-OXOACRIDINE-10-ACETIC ACID, SALTS AND ESTERS THEREOF IN COMBINATION THERAPY OF OVARIAN CANCER ACR, APEH, CA9 KDM4E 2986/4885LMNA 3366/4885L3MBTL1 3600/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.